Last reviewed · How we verify
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions. This observational study was the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Belgium in a clinical practice patient population.
Details
| Lead sponsor | AbbVie |
|---|---|
| Status | COMPLETED |
| Enrolment | 314 |
| Start date | Wed Oct 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Feb 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Hepatitis C, Genotype 1 or 4
Interventions
- Ombitasvir/paritaprevir/ritonavir
- Dasabuvir
- Ribavirin